<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529733</url>
  </required_header>
  <id_info>
    <org_study_id>B10-08</org_study_id>
    <nct_id>NCT04529733</nct_id>
  </id_info>
  <brief_title>Evaluation of the IB10 Sphingotest PCT+ in a Point-of-Care Setting</brief_title>
  <official_title>Evaluation of the IB10 Sphingotest PCT+ in a Point-of-Care Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nexus DX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nexus DX</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the equivalence of IB10 sphingotest PCT+ measurements in point-of-care settings&#xD;
      such as emergency rooms or intensive care units, with corresponding procalcitonin&#xD;
      measurements obtained in a reference or clinical laboratory using a comparative assay, with&#xD;
      respect to the same subset of human EDTA plasma specimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the equivalence of IB10 sphingotest PCT+ measurements in point-of-care settings, with corresponding procalcitonin measurements obtained in a ref or clinical laboratory using a comparative assay, with respect to the same EDTA plasma specimens</measure>
    <time_frame>1 day</time_frame>
    <description>Method comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the equivalence of IB10 sphingotest PCT+ measurements in EDTA whole blood and plasma specimens, as obtained in point-of-care settings as defined above</measure>
    <time_frame>1 day</time_frame>
    <description>Method comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish equivalence of IB10 sphingotest PCT+ measurements in fresh EDTA plasma specimens and frozen EDTA plasma specimens</measure>
    <time_frame>24 hours</time_frame>
    <description>in vitro stability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the precision of IB10 sphingotest PCT+ measurements in point-of-care setting with respect to frozen EDTA plasma specimens</measure>
    <time_frame>1 day</time_frame>
    <description>Point of Care precision Testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the in vitro stability of EDTA whole blood and plasma speciments with respect to procalitonin concentrations as measured by the of IB10 sphingotest PCT+ test.</measure>
    <time_frame>1 day</time_frame>
    <description>in vitro stability</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IB10 sphingotest PCT+</intervention_name>
    <description>Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able and willing to provide written informed consent&#xD;
&#xD;
          -  Subject is 18 years of age or older&#xD;
&#xD;
          -  Subject is presenting with symptoms suggestive of bacterial infection&#xD;
&#xD;
          -  Subject is presenting with two or more of the following symptoms suggestive of&#xD;
             systemic inflammatory response syndrome (SIRS):&#xD;
&#xD;
               -  Body temperature less than 36째C (96.8째F) or greater than 38째C (100.4째F);&#xD;
&#xD;
               -  Heart rate greater than 90 beats per minute;&#xD;
&#xD;
               -  Respiratory rate greater than 20 breaths per minute, or an arterial partial&#xD;
                  pressure of carbon dioxide (pCO2) less than 4.3 kPa (32 mmHg);&#xD;
&#xD;
               -  White blood cell count less than 4,000 cells/mm3 (4 x 109 cells/L) or greater&#xD;
                  than 12,000 cells/mm3 (12 x 109 cells/L);&#xD;
&#xD;
               -  A normal white blood cell count with the presence of greater&#xD;
&#xD;
               -  than 10% immature neutrophils.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects less than 18 years of age;&#xD;
&#xD;
          -  Subjects who do not present with a minimum of two symptoms suggestive of SIRS, as&#xD;
             defined above&#xD;
&#xD;
          -  Subjects unable or unwilling to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

